WO2006108051A3 - Compositions and methods relating to alzheimer's disease - Google Patents

Compositions and methods relating to alzheimer's disease Download PDF

Info

Publication number
WO2006108051A3
WO2006108051A3 PCT/US2006/012681 US2006012681W WO2006108051A3 WO 2006108051 A3 WO2006108051 A3 WO 2006108051A3 US 2006012681 W US2006012681 W US 2006012681W WO 2006108051 A3 WO2006108051 A3 WO 2006108051A3
Authority
WO
WIPO (PCT)
Prior art keywords
polypeptides
disease
metabolites
polynucleotides
antibodies
Prior art date
Application number
PCT/US2006/012681
Other languages
French (fr)
Other versions
WO2006108051A2 (en
Inventor
Howard Schulman
David Lowe
Christopher H Becker
Haihong Zhou
Sushmita Mimi Roy
Original Assignee
Neurodx Llc
Howard Schulman
David Lowe
Christopher H Becker
Haihong Zhou
Sushmita Mimi Roy
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Neurodx Llc, Howard Schulman, David Lowe, Christopher H Becker, Haihong Zhou, Sushmita Mimi Roy filed Critical Neurodx Llc
Publication of WO2006108051A2 publication Critical patent/WO2006108051A2/en
Publication of WO2006108051A3 publication Critical patent/WO2006108051A3/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C12Q1/6876—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
    • C12Q1/6883—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material

Landscapes

  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Organic Chemistry (AREA)
  • Genetics & Genomics (AREA)
  • Zoology (AREA)
  • Analytical Chemistry (AREA)
  • Wood Science & Technology (AREA)
  • Engineering & Computer Science (AREA)
  • Microbiology (AREA)
  • Biochemistry (AREA)
  • Biotechnology (AREA)
  • Molecular Biology (AREA)
  • Biophysics (AREA)
  • Physics & Mathematics (AREA)
  • Pathology (AREA)
  • Immunology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Peptides Or Proteins (AREA)
  • Investigating Or Analysing Biological Materials (AREA)

Abstract

The present invention provides compositions, methods and kits useful for the diagnosis and treatment of Alzheimer's disease (AD). In particular, the invention provides polypeptides and metabolites that are markers of AD, polynucleotides that encode the polypeptides and antibodies that specifically bind to the polypeptides. The invention also provides fragments, precursors, successors and modified versions of the foregoing polypeptides, metabolites, polynucleotides and antibodies. The invention also provides compositions comprising the foregoing polypeptides, metabolites, polynucleotides and antibodies. The invention also provides methods for using the polypeptides, metabolites, polynucleotides and antibodies in the diagnosis and treatment of AD, monitoring progression of the disease and screening of candidate therapeutic compounds.
PCT/US2006/012681 2005-04-05 2006-04-05 Compositions and methods relating to alzheimer's disease WO2006108051A2 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US66824505P 2005-04-05 2005-04-05
US60/668,245 2005-04-05

Publications (2)

Publication Number Publication Date
WO2006108051A2 WO2006108051A2 (en) 2006-10-12
WO2006108051A3 true WO2006108051A3 (en) 2008-10-09

Family

ID=37074067

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US2006/012681 WO2006108051A2 (en) 2005-04-05 2006-04-05 Compositions and methods relating to alzheimer's disease

Country Status (1)

Country Link
WO (1) WO2006108051A2 (en)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7851172B2 (en) 2006-07-25 2010-12-14 University Of Kentucky Research Foundation Biomarkers of mild cognitive impairment and alzheimer's disease
JP6012923B2 (en) 2010-12-22 2016-10-25 株式会社Ｍｃｂｉ Biomarker for cognitive dysfunction disease and method for detecting cognitive dysfunction disease using the biomarker
FI20115576A0 (en) * 2011-06-10 2011-06-10 Teknologian Tutkimuskeskus Vtt Oy A method for diagnosing Alzheimer's disease
GB2511525A (en) * 2013-03-05 2014-09-10 Randox Teoranta Methods and Compositions for the Diagnosis of Alzheimer's Disease
JP6193942B2 (en) * 2015-09-09 2017-09-06 株式会社Ｍｃｂｉ Biomarker for cognitive dysfunction disease and method for detecting cognitive dysfunction disease using the biomarker
CN110195073B (en) * 2019-06-12 2021-01-01 华中农业大学 Trypsin precursor gene and protein coded by trypsin precursor gene, interfering RNA (ribonucleic acid) and application of trypsin precursor gene

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20030064411A1 (en) * 2000-12-08 2003-04-03 Herath Herath Mudiyanselage Athula Chandrasiri Nucleic acid molecules, polypeptides and uses therefor, including diagnosis and treatment of Alzheimer's disease
US20030180959A1 (en) * 2001-12-10 2003-09-25 Xianlin Han Diagnostic for early stage Alzheimer's disease

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20030064411A1 (en) * 2000-12-08 2003-04-03 Herath Herath Mudiyanselage Athula Chandrasiri Nucleic acid molecules, polypeptides and uses therefor, including diagnosis and treatment of Alzheimer's disease
US20030180959A1 (en) * 2001-12-10 2003-09-25 Xianlin Han Diagnostic for early stage Alzheimer's disease

Also Published As

Publication number Publication date
WO2006108051A2 (en) 2006-10-12

Similar Documents

Publication Publication Date Title
WO2006020269A3 (en) Biomarkers of neurodegenerative disease
WO2007103770A8 (en) Compositions and methods for analyzing renal cancer
WO2007011907A3 (en) Alpha-synuclein antibodies and methods related thereto
MX2009012949A (en) Humanized antibodies which bind to aî² (1-42) globulomer and uses thereof.
WO2005011599A3 (en) Antibodies specific for toxic amyloid beta protein oligomers
MX2009012950A (en) Humanized antibodies to aãŸ(20-42) globulomer and uses thereof.
WO2007016548A3 (en) Micro-rna-based methods and compositions for the diagnosis, prognosis and treatment of breast cancer
WO2005107491A3 (en) Multi-lectin affinity chromatography and uses thereof
EA200901436A1 (en) Antigen-binding proteins that bind PAR-2
WO2007092640A3 (en) Antibodies that bind par-2
WO2006099698A3 (en) Novel anti-plgf antibody
WO2006073941A3 (en) Polypeptides that bind br3 and uses thereof
DK2527315T3 (en) Compounds, compositions and methods for the treatment of amyloid diseases and synucleinopathies such as Alzheimer's disease, type 2 diabetes and Parkinson's disease
WO2004106380A3 (en) Human-anti-human cd3 binding molecules
UA96139C2 (en) Anti-neuropilin-1 (nrp1) antibody
WO2006078576A3 (en) Aminomethyl beta-secretase inhibitors for the treatment of alzheimer's disease
WO2006108051A3 (en) Compositions and methods relating to alzheimer's disease
EA200801174A1 (en) GLP-2 MIMETIC ANTIBODIES, POLYPEPTIDES, COMPOSITIONS, METHODS AND APPLICATIONS
WO2006094014A3 (en) Methods for diagnosis and treatment of endometrial cancer
WO2006053315A3 (en) Methods and compositions for treating cellular proliferative diseases
WO2005113831A3 (en) Biomarkers for multiple sclerosis and methods of use thereof
WO2007059064A3 (en) Fgf2-related methods for diagnosing and treating depression
WO2008151819A3 (en) Treatment of tumors using specific anti-l1 antibody
WO2006058720A3 (en) Novel compounds for the treatment of neurological disorders
ZA200702318B (en) Nanobodies against amyloid-beta and polypeptides comprising the same for the treatment of degenerative neual diseases such as alzheimer's disease

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application
NENP Non-entry into the national phase

Ref country code: DE

NENP Non-entry into the national phase

Ref country code: RU

32PN Ep: public notification in the ep bulletin as address of the adressee cannot be established

Free format text: NOTIFICATION OF LOSS OF RIGHTS PURSUANT TO RULE 112(1) EPC (EPO FORM 1205A SENT ON 07.04.2008)

122 Ep: pct application non-entry in european phase

Ref document number: 06740570

Country of ref document: EP

Kind code of ref document: A2